Systematic review of 22 studies (4 meta-analysed) in triple-negative breast cancer with residual disease after neoadjuvant therapy: post-treatment ctDNA positivity was associated with poorer recurrence-related outcomes (pooled HR 4.63); few studies contributed.
Meta-analysisn = 22 studies
Barjij et al. Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis